Publication

Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders

Kok, T., Wasiel, A. A., Cool, R. H., Melgert, B. N., Poelarends, G. J. & Dekker, F. J., Nov-2018, In : Drug Discovery Today. 23, 11, p. 1910-1918 9 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

DOI

Macrophage migration inhibitory factor (MIF) is an important cytokine for which an increasing number of functions is being described in the pathogenesis of inflammation and cancer. Nevertheless, the availability of potent and druglike MIF inhibitors that are well-characterized in relevant disease models remains limited. Development of highly potent and selective small-molecule MIF inhibitors and validation of their use in relevant disease models will advance drug discovery. In this review, we provide an overview of recent advances in the identification of MIF as a pharmacological target in the pathogenesis of inflammatory diseases and cancer. We also give an overview of the current developments in the discovery and design of small-molecule MIF inhibitors and define future aims in this field.

Original languageEnglish
Pages (from-to)1910-1918
Number of pages9
JournalDrug Discovery Today
Volume23
Issue number11
Early online date21-Jun-2018
Publication statusPublished - Nov-2018

    Keywords

  • TAUTOMERASE INHIBITORS, STRUCTURAL FEATURES, ENZYMATIC-ACTIVITY, IN-VITRO, CANCER, CYTOKINE, TARGET, DISCOVERY, GROWTH, ANTAGONISTS

View graph of relations

Download statistics

No data available

ID: 62128783